EIF2A and cancer: The haem‐regulated inhibitor activating compounds 1‐((1,4‐trans)‐4‐aryloxycyclohexyl)‐3‐arylureas increased p‐eIF2α levels, downstream of the ISR and slowed cancer cell proliferation (Chen et al., 2013).